表紙
市場調査レポート

ヒトパピローマウィルス(HPV)感染症のパイプライン分析

Human Papillomavirus Infections Pipeline Analysis

発行 PNS Pharma 商品コード 308691
出版日 ページ情報 英文 197 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
ヒトパピローマウィルス(HPV)感染症のパイプライン分析 Human Papillomavirus Infections Pipeline Analysis
出版日: 2014年06月01日 ページ情報: 英文 197 Pages
概要

当レポートでは、ヒトパピローマウィルス(HPV)感染症治療薬市場について調査し、市場概要、上市薬のプロファイル・特許分析、フェーズ・国別の治験分析、臨床開発段階の薬剤、治験が停止・中止された薬剤のプロファイルおよび競合情勢などをまとめ、お届けいたします。

第1章 世界におけるヒトパピローマウィルス(HPV)感染治療薬市場の概要

第2章 ヒトパピローマウィルス(HPV)感染治療薬の治験分析:フェーズ・国別

  • 未確認段階
  • 研究
  • 前臨床
  • 臨床
  • フェーズ0
  • フェーズI
  • フェーズI/II
  • フェーズII
  • フェーズII/III
  • フェーズIII

第3章 上市済みヒトパピローマウィルス(HPV)治療薬のプロファイル

  • ガーダシル
  • サーバリックス
  • Zyclara
  • イントロンA
  • Yallaferon
  • ReliFeron
  • Alferon N
  • Veregen/Polyphenon E
  • Dermojuventus

第4章 未開発・中止されたHPV治療薬のプロファイル

  • 未開発
  • 中止
  • 市場撤退

第5章 競合情勢

  • Advanced Viral Research
  • Biogen Idec
  • BioSphings
  • EyeGene
  • Helix BioPharma
  • Inviragen
  • MedImmune
  • Merck & Co
  • Valeant Pharmaceuticals

図表リスト

目次

Currently there is significant amount of research being undertaken to study the process of HPV infection causing precancerous changes in normal cells. Also, methods to prevent and manage this situation are also being analyzed. A majority of these studies were previously focusing on cervical cells in women. But in recent years, the realm of research has been extended to other tissues also in which HPV may cause cancer, such as the oropharynx and anus. Also, many organizations are analyzing the use of second-generation preventive vaccines along with therapeutic HPV vaccines, which could possibly prevent the development of cancer among women previously infected with HPV. Such an “ideal” vaccine strategy would combine a preventive and therapeutic vaccine, which would help in a major way.

The mechanism of the HPV vaccines is similar to the other immunizations which help in protecting against viral infections. It has been observed and analyzed that the unique surface components of HPV have the capability to create an antibody response which could possibly protect the human body against infection. These components could thus be used as a basis of the vaccine. There are only 2 HPV vaccines which are currently marketed across the globe. Both these vaccines are prepared using the recombinant technology, which is taken from purified L1 structural proteins which self assemble to form HPV type-specific empty shells or virus-like particles (VLPs).

Since there are no therapeutic HPV vaccines available at present which have proved their efficiency in the clinical trials, there is still a lot of work which is required in this field, thus opening a large window of opportunities. There have been some technological advancements in the past 4-5 years. The future is also likely to continue to witness similar technological and medical success in terms of new drugs and efficient vaccines, with the help of adequate funding. Certain developments like a new treatment to reduce transmissibility in drug users and new efforts to strengthen the immune system have the potential to develop further and provide better healthcare services to the patients in the future. Thus, there needs to be more focus being given to increasing the knowledge and awareness about HPV infections and the ways and methods to treat it, either through drugs or through vaccines.

“Human Papillomavirus Infections Vaccine Pipeline Analysis” Report Highlights:

  • Human Papillomavirus Vaccine Market Overview
  • Marketed Drug Profiles & Patent Analysis
  • Clinical Trial Insight by Phase & Country
  • Drug Clinical Development Phase: 47
  • Suspended & Discontinued Drug Profiles: 46
  • Competitive Landscape

Table of Contents

1. Global Human Papillomavirus Infection Drug Market Overview

  • 1.1. Market Overview
  • 1.2. Clinical Pipeline Insight

2. Human Papillomavirus Infections Drug Clinical Trial Insight by Phase & Country

  • 2.1. Unknown Phase
  • 2.2. Research
  • 2.3. Preclinical
  • 2.4. Clinical
  • 2.5. Phase-0
  • 2.6. Phase-I
  • 2.7. Phase-I/II
  • 2.8. Phase-II
  • 2.9. Phase-II/III
  • 2.10. Phase-III

3. Marketed Human Papillomavirus Drug Profile

  • 3.1. Gardasil
  • 3.2. Cervarix
  • 3.3. Zyclara
  • 3.4. Intron A
  • 3.5. Yallaferon
  • 3.6. ReliFeron
  • 3.7. Alferon N
  • 3.8. Veregen/Polyphenon E
  • 3.9. Dermojuventus

4. No Development Reported & Discontinued HPV Drug Profiles

  • 4.1. No Development Reported
  • 4.2. Discontinued
  • 4.3. Market Withdrawal

5. Competitive Landscape

  • 5.1. Advanced Viral Research
  • 5.2. Biogen Idec
  • 5.3. BioSphings
  • 5.4. EyeGene
  • 5.5. Helix BioPharma
  • 5.6. Inviragen
  • 5.7. MedImmune
  • 5.8. Merck & Co
  • 5.9. Valeant Pharmaceuticals
  • Figure 1-1: HPV Infections Clinical Pipeline by Phase (%), 2014
  • Figure 1-2: HPV Infections Clinical Pipeline by Phase (Number), 2014
  • Figure 1-3: No Development Reported in HPV Infections Clinical Pipeline by Phase (%), 2014
  • Figure 1-4: No Development Reported in HPV Infections Clinical Pipeline by Phase (Number), 2014
  • Figure 1-5: Discontinued HPV Infections Clinical Pipeline by Phase (%), 2014
  • Figure 1-6: Discontinued HPV Infections Clinical Pipeline by Phase (Number), 2014

List of Tables

Following Information For Each Drug Profile in Covered in More than 200 Tables in Report:

  • Drug Profile Overview
  • Active Indication
  • Phase of Development
  • Country for Clinical Trial
  • Owner / Originator/ Licensee/Collaborator
  • Administrative Route
  • Drug Class
Back to Top